Votre événement devrait être ici ! Pour référencer, gérer, promouvoir... Pour s'informer ou se former ... Inscriptions en ligne

Langue du site : Français - English
Réf : 32519
Evènement :Change Control Best Practices - Avoiding Unintended Consequences of Changes

Dates :Jeudi 28 Janvier 2021 - Vendredi 29 Janvier 2021

Lieu :San Jose, California, États-Unis

Type :Conférence & Séminaire - Audience Internationale

Accréditation :--




One of the top 10 FDA 483 and Warning Letter citations is for inadequate change control. Change control receives detailed scrutiny during FDA inspections, and FDA reviews change control documentation to determine that changes did not adversely impact products, processes, equipment, facilities, etc. A single inadequate change may lead to significant negative events, including release of sub-standard product or product recall. A pattern of inadequate changes may require costly and time-consuming system remediation efforts.


  • Understand the purpose of change control
  • Understand regulatory requirements and FDA expectations for change control
  • Identify what types of changes are /are not subject to change control
  • Properly describe changes
  • Properly justify changes
  • Develop a comprehensive Change Execution Plan
  • Conduct a proper change Risk Assessment
  • Ensure proper execution of changes
  • Ensure proper implementation of changes
  • Develop a complete Change Control documentation package
  • Utilize critical thinking skills throughout the change control process
  • Avoid pitfalls during the change control process


Day 01(6:00 AM to 12:00 PM PST)
  • Regulatory Requirements
  • FDA Change Control Expectations / Warning Letter Examples
  • Purpose of Change Controls
    • What is Change Control?
    • Why / When Change Control?
    • Physical Changes vs. Document Changes
  • Change Control Process
    • Change Control Process Model- Integrated Manufacturers
    • Change Control Process Model- Sponsor Oversight of CMO Changes
  • Types of Changes Subject to Change Control
    • Products, Materials, Suppliers, Processes, Facilities, Equipment, etc.
    • Like-for-Like Changes
    • Emergency Changes
    • Case Study # 1- Change Control: Yes or No?
  • Change Proposal
    • Change Proposal Elements
    • Describing the Change
    • Case Study # 2- Change Proposal
  • Change Justification
    • Change Justification Elements
    • Change Risk Assessment
    • Case Study # 3- Change Justification
  • Change Execution Plan
    • Change Execution Plan Elements
    • Case Study # 4- Change Execution Plan
  • Change Proposal Assessment
    • SME Assessments (by functional area)
    • Case Study # 5- Change Proposal Assessment
Day 02(6:00 AM to 12:00 PM PST)
  • Change Execution
    • Key Considerations for Executing Changes
    • Evidence of Change Completion
    • Change Amendment / Cancellation
  • Change Implementation
    • Key Considerations for Implementing Changes
    • Assessing Change Effectiveness
  • Change Control Documentation
    • Change Documentation Package Elements
  • Putting It All Together: A System Viewpoint



Andrew Campbell has 25 years of pharmaceutical quality assurance and quality systems experience in both industry and consulting roles. Mr. Campbell has worked in clinical supply and commercial manufacturing environments, and has experience with integrated manufacturing and contract manufacturing business models. He has extensive expertise in the areas of deviation - CAPA, change control, GMP auditing, GMP training, and regulatory inspection preparation and management.

Working with large and small companies, Mr. Campbell has successfully developed, remediated and implemented key quality systems. He is a skilled GMP auditor, and has audited multiple API, drug product, packaging, testing, and distribution facilities. He is an experienced GMP trainer, and has developed customized and interactive training presentations for many companies. He has also provided FDA inspection support for several clients, including readiness training, on-site assistance during inspections, and authoring written responses to inspectional observations. Prior to becoming a consultant in 2007, Mr. Campbell worked for Ligand Pharmaceuticals as director of quality systems.


Organizing committee



Plan et itinéraire
Adresse de la conférence :
San Jose
California, États-Unis
Tél : +1-888-717-2436
Plan et itinéraire


Pour accéder aux informations vous devez être connecté. Créer un compte est facile et gratuit!

Connexion à votre compte
S'inscrire sur Doctorama


Change Control Best Practices - Avoiding Unintended Consequences of Changes Pharmacie
change control process, change execution plan, fda change control expectations, change control best practices, change control procedure fda, fda guidance change control, fda management of change, fda document control
-- -- --


Pour plus d'informations sur Change Control Best Practices - Avoiding Unintended Consequences of Changes, veuillez contacter ComplianceOnline

Pour afficher le site de l'annonceur, obtenir une lettre d'invitation, vous devez être connecté

Connexion à votre compte
S'inscrire sur Doctorama

Recommander cet évènement